Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 4:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 646 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Combination of treatment modalities Clear all
Not listed Phase 2 Interventional

A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation

NCT04308837
View directory record Official record
Conditions
Gastric Cancer, Stomach Cancer
Interventions
Paclitaxel, Carboplatin, Dexamethasone, Diphenhydramine, Famotidine, Palonosetron, 3D conformal or intensity modulated radiotherapy, Surgical resection, Adjuvant Chemotherapy
Drug · Radiation · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 1, 2026, 4:29 PM EDT
Completed Phase 2 Interventional Results available

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

NCT01226719
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Panitumumab, Oxaliplatin, Irinotecan, Leucovorin, 5-Fluorouracil
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
15
States / cities
Jonesboro, Arkansas • Fort Myers, Florida • Orlando, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 1, 2026, 4:29 PM EDT
Completed Not applicable Interventional

The Evaluation of a Novel Treatment Algorithm for Patients With Patellofemoral Syndrome

NCT01767246
View directory record Official record
Conditions
Patellofemoral Syndrome
Interventions
PFS Algorithm treatment, Multimodal treatment
Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
12 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Columbus, Ohio • Westerville, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 7, 2015 · Synced Oct 1, 2026, 4:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

HIPEC After Radical Cystectomy for High Risk Bladder Cancer

NCT03514888
View directory record Official record
Conditions
Invasive Bladder Cancer
Interventions
HIPEC
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
45 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Oct 1, 2026, 4:29 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The Synergistic Effects of AIH and FES in Persons With MS

NCT06413602
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Interventions
Acute Intermittent Hypoxia, Neuromuscular Electrical Stimulation
Other
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 1, 2026, 4:29 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Head and Neck Cancer

NCT00404339
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
mutant p53 peptide pulsed dendritic cell vaccine, tetanus toxoid helper peptide, adjuvant therapy
Biological · Procedure
Lead sponsor
Robert Ferris
Other
Eligibility
18 Years to 120 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Oct 1, 2026, 4:29 PM EDT
Recruiting Not applicable Interventional

Comparing Prism Adaptation Training With and Without TENS to Minimize Unilateral Spatial Neglect

NCT07157865
View directory record Official record
Conditions
Unilateral Spatial Neglect, Stroke
Interventions
Prism adaptation training combined with TENS, PAT only
Device · Other
Lead sponsor
Kettering Health Network
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Centerville, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 1, 2026, 4:29 PM EDT
Completed Phase 1 Interventional

PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck

NCT00011778
View directory record Official record
Conditions
Squamous Cell Carcinoma
Interventions
bortezomib, radiation therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 1, 2026, 4:29 PM EDT
Completed Phase 2 Interventional

GM-CSF and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Colon Cancer

NCT00262808
View directory record Official record
Conditions
Colorectal Cancer
Interventions
sargramostim, fluorouracil, leucovorin calcium, oxaliplatin, adjuvant therapy, conventional surgery, neoadjuvant therapy
Biological · Drug · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Rochester, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2013 · Synced Oct 1, 2026, 4:29 PM EDT
Recruiting Not applicable Interventional

Perspectives on Spinal Manipulative Therapy for Low Back Pain

NCT06590116
View directory record Official record
Conditions
Low Back Pain
Interventions
Physical therapy, Physical therapist provider
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 1, 2026, 4:29 PM EDT
Completed Phase 2 Interventional Results available

Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

NCT02296684
View directory record Official record
Conditions
Cancer of Head and Neck, Head and Neck Cancer, Neoplasms, Head and Neck, Carcinoma, Squamous Cell of Head and Neck, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head and Neck
Interventions
MK-3475 (neoadjuvant), Surgery, Intensity modulated radiation therapy, Image-guided radiation therapy, Cisplatin, MK-3475 (adjuvant), Peripheral blood
Biological · Procedure · Radiation + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
3
States / cities
Boston, Massachusetts • St Louis, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 1, 2026, 4:29 PM EDT
Active, not recruiting Early Phase 1 Interventional

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

NCT05415709
View directory record Official record
Conditions
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Serous Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IIIA Fallopian Tube Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Primary Peritoneal Cancer AJCC v8, Stage IIIA1 Fallopian Tube Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Fallopian Tube Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Fallopian Tube Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Primary Peritoneal Cancer AJCC v8, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8
Interventions
Carboplatin, Cisplatin, Cytoreductive Surgery, Hyperthermic Intraperitoneal Chemotherapy, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration, Biospecimen Collection, Diagnostic Imaging
Drug · Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 1, 2026, 4:29 PM EDT
Terminated Not applicable Interventional Results available

Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer

NCT01275664
View directory record Official record
Conditions
Nausea and Vomiting, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Stage II Ovarian Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Undifferentiated Ovarian Carcinoma
Interventions
Adjuvant Therapy, Aprepitant, Carboplatin, Cisplatin, Dexamethasone, Granisetron Transdermal Patch, Management of Therapy Complications, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
2
States / cities
Hinsdale, Illinois • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 1, 2026, 4:29 PM EDT
Terminated No phase listed Observational

Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma With Peritoneal Carcinomatosis

NCT02420509
View directory record Official record
Conditions
Cancer
Interventions
systemic chemotherapy
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 1, 2026, 4:29 PM EDT
Terminated Phase 1 Interventional

FOLFIRINOX + NIS793 in Pancreatic Cancer

NCT05417386
View directory record Official record
Conditions
Pancreas Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
Interventions
FOLFIRINOX, Oxaliplatin, Leucovorin, Irinotecan, 5-Fluorouracil (5-FU), NIS793, Chemoradiation, Capecitabine, Radiation Therapy, Surgery
Drug · Radiation · Procedure
Lead sponsor
Colin D. Weekes, M.D., PhD
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 1, 2026, 4:29 PM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID)

NCT05855369
View directory record Official record
Conditions
Smell Dysfunction, Olfactory Disorder, Long COVID
Interventions
Trigeminal Nerve Stimulation (TNS), Active Smell Training (ST), Placebo Smell Training (PBO)
Device · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 1, 2026, 4:29 PM EDT
Completed Phase 2 Interventional

Combination Therapy With Dalfampridine and Locomotor Training for Chronic, Motor Incomplete Spinal Cord Injury

NCT01621113
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Dalfampridine, Placebo
Drug
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 1, 2026, 4:29 PM EDT
Not listed Phase 2 Interventional

Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer

NCT00491816
View directory record Official record
Conditions
Breast Cancer
Interventions
Erlotinib with neoadjuvant chemotherapy
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 1, 2026, 4:29 PM EDT
Completed Phase 2 Interventional

Cellular Adoptive Immunotherapy in Treating Patients With Glioblastoma Multiforme

NCT00331526
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
aldesleukin, therapeutic autologous lymphocytes, adjuvant therapy, conventional surgery
Biological · Procedure
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
16 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2013 · Synced Oct 1, 2026, 4:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

To Study the Mechanisms of Acupuncture Through Functional Magnetic Resonance Imaging and Peripheral Neurosensory Testing

NCT00521547
View directory record Official record
Conditions
Healthy
Interventions
Electroacupuncture
Procedure
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2007 · Synced Oct 1, 2026, 4:29 PM EDT
Completed Phase 2 Interventional Results available

Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy

NCT01265433
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
Galinpepimut-S + Montanide + GM-CSF, Montanide + GM-CSF
Biological
Lead sponsor
Sellas Life Sciences Group
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 1, 2026, 4:29 PM EDT
Terminated No phase listed Observational Results available

Alloantibodies in Pediatric Heart Transplantation

NCT01005316
View directory record Official record
Conditions
Pediatric Heart Transplantation, Pediatric Heart Transplant Recipients
Interventions
Induction Therapy, Tacrolimus, Mycophenolate Mofetil, Intraoperative plasma exchange/pheresis, Short-term post-operative plasmapheresis, Immunoglobulins, Intravenous, Prednisone
Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 21 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
7
States / cities
Boston, Massachusetts • St Louis, Missouri • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 1, 2026, 4:29 PM EDT
Terminated Phase 1 Interventional

Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery

NCT00290719
View directory record Official record
Conditions
Esophageal Cancer
Interventions
cisplatin, gefitinib, irinotecan hydrochloride, conventional surgery, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 1, 2026, 4:29 PM EDT
Active, not recruiting Not applicable Interventional

Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients)

NCT01817192
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay
Drug · Other
Lead sponsor
Razor Genomics
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
18
States / cities
Mission Viejo, California • Sacramento, California • Santa Rosa, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 1, 2026, 4:29 PM EDT